A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)
Status:
Completed
Trial end date:
2013-09-17
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of
MK-8521.
Part 1 primary hypothesis: Administration of single subcutaneous (SC) doses of MK-8521 is
sufficiently safe and well- tolerated in healthy participants, based on assessment of
clinical and laboratory adverse experiences, to permit continued clinical investigation.
Part 2: Administration of multiple once daily SC doses of MK-8521 is sufficiently safe and
well-tolerated in healthy lean and obese participants, based on assessment of clinical and
laboratory adverse experiences, to permit continued clinical investigation.